Nanohale AG (FYB) | WebDisclosure

Basculer en Français

8295	Companies
114858	Keywords
55302	Articles
62445	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 11/19/2024 at 06:35, 2 days 5 hours ago

Formycon annonce une conférence téléphonique sur les résultats financiers et une participation à la conférence

Résultats Financiers Formycon AG Bourse De Francfort Conférence Des Investisseurs Conférence Téléphonique Sur Les Résultats Financiers
BRIEF

published on 11/19/2024 at 06:35, 2 days 5 hours ago

Formycon Announces Earnings Call and Conference Participation

Financial Results Investor Conference Frankfurt Stock Exchange Formycon AG Earnings Call
PRESS RELEASE

published on 11/19/2024 at 06:30, 2 days 6 hours ago

Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences
Formycon AG invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences. Management Board to discuss key financial figures and recent uplisting to the Prime Standard of Frankfurt Stock Exchange

Investor Conferences Formycon AG Biosimilars Earnings Call Nine-month Results
BRIEF

published on 11/18/2024 at 06:35, 3 days 5 hours ago

Le biosimilaire FYB203 de Formycon reçoit un avis positif du CHMP

Formycon AG Biosimilaire FYB203 Approbation Du CHMP Aflibercept
BRIEF

published on 11/18/2024 at 06:35, 3 days 5 hours ago

Formycon's FYB203 Biosimilar Receives Positive CHMP Opinion

Formycon AG Biosimilar FYB203 CHMP Approval Aflibercept
PRESS RELEASE

published on 11/18/2024 at 06:30, 3 days 6 hours ago

Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama®
Formycon receives positive CHMP opinion for FYB203, a biosimilar candidate to Eylea, under tradenames AHZANTIVE and Baiama. Approval decision by European Commission expected in January 2025

Formycon Eylea CHMP Opinion Biosimilar Candidate AHZANTIVE
BRIEF

published on 11/15/2024 at 18:23, 5 days 18 hours ago

Positive CHMP Opinion for Formycon's Aflibercept-Biosimilar FYB203

Formycon AG FYB203 CHMP Opinion EMA Approval Biosimilar Drug
BRIEF

published on 11/15/2024 at 18:23, 5 days 18 hours ago

Avis positif du CHMP pour le biosimilaire Aflibercept FYB203 de Formycon

Formycon AG FYB203 Avis Du CHMP Approbation De L'EMA Médicament Biosimilaire
PRESS RELEASE

published on 11/15/2024 at 18:18, 5 days 18 hours ago

EQS-Adhoc: Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
Formycon AG announces positive CHMP opinion from EMA for Aflibercept-Biosimilar FYB203 (AHZANTIVE®/ Baiama®) as a treatment for retinal diseases. Market approval expected by January 2025

Formycon AG EMA Retinal Diseases CHMP Opinion Aflibercept-Biosimilar FYB203
BRIEF

published on 11/11/2024 at 17:46, 9 days 18 hours ago

Formycon AG Extends CEO Contract and Joins Prime Standard

Frankfurt Stock Exchange Formycon AG Biosimilars Prime Standard Stefan Glombitza

Accesswire

Published on 11/21/2024 at 12:00, 31 minutes ago

Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 31 minutes ago

Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 1 minute ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 28 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 31 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:15, 15 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 24 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 30 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 11:01, 1 hour 29 minutes ago

Original-Research: SMT Scharf AG (von Montega AG): Kaufen

Les Echos

Published on 11/21/2024 at 06:58, 5 hours 33 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 33 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 33 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 23 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 10 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE